1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H1N1 Subtype Infections - Drugs In Development, 2021, provides an overview of the Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
H1N1 Infection also called as swine flu is a new kind of flu in humans. It's caused by a contagious virus. H1N1 flu infects the breathing tubes in nose, throat, and lungs. The disease is contagious. When people who have it cough or sneeze, they spray tiny drops of the virus into the air. Signs and symptoms include cough, fever, sore throat, stuffy or runny nose, body aches, headache and fatigue. Treatment includes medication (antiviral drugs).
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H1N1 Subtype Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 7, 11, 7, 2, 43, 8 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 3, 2, 12 and 2 molecules, respectively.
Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H1N1 Subtype Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionInfluenza A Virus, H1N1 Subtype Infections - Overview
- Influenza A Virus, H1N1 Subtype Infections - Therapeutics Development
Influenza A Virus, H1N1 Subtype Infections - Companies Involved in Therapeutics Development
Influenza A Virus, H1N1 Subtype Infections - Drug Profiles
Influenza A Virus, H1N1 Subtype Infections - Dormant Projects
Influenza A Virus, H1N1 Subtype Infections - Discontinued Products
Influenza A Virus, H1N1 Subtype Infections - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, 2021
- Number of Products under Development by Companies, 2021
- Number of Products under Development by Universities/Institutes, 2021
- Products under Development by Companies, 2021
- Products under Development by Universities/Institutes, 2021
- Number of Products by Stage and Target, 2021
- Number of Products by Stage and Mechanism of Action, 2021
- Number of Products by Stage and Route of Administration, 2021
- Number of Products by Stage and Molecule Type, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by AbbVie Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Abzyme Therapeutics LLC, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Adimmune Corp, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Akshaya Bio Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Alla Chem LLC, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Allergy Therapeutics Plc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by AlphaVax Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Altimmune Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Ansun Biopharma Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by AstraZeneca Plc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by AVM Biotechnology LLC, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by BioTherapeutics Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Blue Water Vaccines Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by BlueWillow Biologics Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Brandenburg Antiinfektiva GmbH, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by BunyaVax BV, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by CEL-SCI Corp, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Celestial Therapeutics Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Changchun Bcht Biotechnology Co Ltd, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Chicago Biosolutions Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by CHO Pharma Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cidara Therapeutics Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cilian AG, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cocrystal Pharma Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by CSL Ltd, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Curevac NV, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by CytoAgents Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cytocom Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Dnarx LLC, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Emergent BioSolutions Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Ena Respiratory Pty Ltd, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Ena Therapeutics Pty Ltd, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by EpiVax Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Etubics Corp, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by ExpreS2ion Biotech Holding AB, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by FluGen Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Gamma Vaccines Pty Ltd, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Genentech USA Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by GlaxoSmithKline Plc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Greffex Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by ILiAD Biotechnologies LLC, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Imutex Ltd, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Institute of Virology Vaccines and Sera Torlak, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by InvVax Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Jiangsu Ab&b Biotechnology Co Ltd, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Johnson & Johnson, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Liaoning Cheng Da Biotechnology Co Ltd, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Medicago Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Microbiotix Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by NanoViricides Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by New Amsterdam Sciences Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Novavax Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by NuGenerex Immuno-Oncology Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by PeptiDream Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Pneumagen Ltd, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Recce Pharmaceuticals Ltd, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Replikins Ltd, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Revelation Biosciences Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by SAB Biotherapeutics Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Sanofi, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Sciogen Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Seqirus Ltd, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Serum Institute of India Pvt Ltd, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Shanghai Institute of Biological Products Co Ltd, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Sonnet BioTherapeutics Holdings Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by TechnoVax Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Tiba Biotech LLC, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Trellis Bioscience Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by UMN Pharma Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vaccibody AS, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vacthera BioTech GmbH, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vaxart Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vaxxas Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Viramatix Sdn Bhd, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Virion Biotherapeutics, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vironova Medical AB, 2021
- Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vivaldi Biosciences Inc, 2021
- Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, 2021
- Influenza A Virus, H1N1 Subtype Infections - Discontinued Products, 2021
List of Figures
- Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, 2021
- Number of Products under Development by Companies, 2021
- Number of Products under Development by Universities/Institutes, 2021
- Number of Products by Top 10 Targets, 2021
- Number of Products by Stage and Top 10 Targets, 2021
- Number of Products by Top 10 Mechanism of Actions, 2021
- Number of Products by Stage and Top 10 Mechanism of Actions, 2021
- Number of Products by Top 10 Routes of Administration, 2021
- Number of Products by Stage and Top 10 Routes of Administration, 2021
- Number of Products by Top 10 Molecule Types, 2021
- Number of Products by Stage and Top 10 Molecule Types, 2021
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Abzyme Therapeutics LLC
- Adimmune Corp
- Akshaya Bio Inc
- Alla Chem LLC
- Allergy Therapeutics Plc
- AlphaVax Inc
- Altimmune Inc
- Ansun Biopharma Inc
- AstraZeneca Plc
- AVM Biotechnology LLC
- BioTherapeutics Inc
- Blue Water Vaccines Inc
- BlueWillow Biologics Inc
- Brandenburg Antiinfektiva GmbH
- BunyaVax BV
- CEL-SCI Corp
- Celestial Therapeutics Inc
- Changchun Bcht Biotechnology Co Ltd
- Chicago Biosolutions Inc
- CHO Pharma Inc
- Cidara Therapeutics Inc
- Cilian AG
- Cocrystal Pharma Inc
- CSL Ltd
- Curevac NV
- CytoAgents Inc
- Cytocom Inc
- Dnarx LLC
- Emergent BioSolutions Inc
- Ena Respiratory Pty Ltd
- Ena Therapeutics Pty Ltd
- EpiVax Inc
- Etubics Corp
- ExpreS2ion Biotech Holding AB
- FluGen Inc
- Gamma Vaccines Pty Ltd
- Genentech USA Inc
- GlaxoSmithKline Plc
- Greffex Inc
- ILiAD Biotechnologies LLC
- Imutex Ltd
- Inovio Pharmaceuticals Inc
- Institute of Virology Vaccines and Sera Torlak
- InvVax Inc
- Jiangsu Ab&b Biotechnology Co Ltd
- Jiangsu Kanion Pharmaceutical Co Ltd
- Johnson & Johnson
- Liaoning Cheng Da Biotechnology Co Ltd
- Medicago Inc
- Microbiotix Inc
- NanoViricides Inc
- New Amsterdam Sciences Inc
- Novavax Inc
- NuGenerex Immuno-Oncology Inc
- PeptiDream Inc
- Pneumagen Ltd
- Recce Pharmaceuticals Ltd
- Replikins Ltd
- Revelation Biosciences Inc
- SAB Biotherapeutics Inc
- Sanofi
- Sciogen Inc
- Seqirus Ltd
- Serum Institute of India Pvt Ltd
- Shanghai Institute of Biological Products Co Ltd
- Sonnet BioTherapeutics Holdings Inc
- TechnoVax Inc
- Tiba Biotech LLC
- Trellis Bioscience Inc
- UMN Pharma Inc
- Vaccibody AS
- Vacthera BioTech GmbH
- Vaxart Inc
- Vaxxas Inc
- Viramatix Sdn Bhd
- Virion Biotherapeutics
- Vironova Medical AB
- Vivaldi Biosciences Inc
